Mirum Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Mirum Pharmaceuticals, Inc. (MIRM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $30.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $30.61M, a 65.77% increase year-over-year.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $22.34M, a 41.31% increase year-over-year.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $18.19M, a 51.48% increase year-over-year.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $18.46M, a 51.38% increase year-over-year.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $71.52M, a 45.28% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $49.23M, a 37.34% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $35.84M, a 30.59% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $27.45M, a 18.89% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 8 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $30.61M 10-Q · filed 2026-08-05 | $52.95M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $22.34M 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $71.52M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $18.19M 10-Q · filed 2025-11-04 | $36.66M derived: sum of 2 quarters · filed 2026-08-05 | $52.47M derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $18.46M 10-Q · filed 2026-08-05 | $34.27M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $15.81M 10-Q · filed 2026-08-05 | ||||
| 2024-12-31 | $49.23M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $12.01M 10-Q · filed 2025-11-04 | $24.21M derived: sum of 2 quarters · filed 2025-11-04 | $35.87M derived: sum of 3 quarters · filed 2025-11-04 | ||
| 2024-06-30 | $12.20M 10-Q · filed 2025-11-04 | $23.86M derived: sum of 2 quarters · filed 2025-11-04 | |||
| 2024-03-31 | $11.66M 10-Q · filed 2025-11-04 | ||||
| 2023-12-31 | $35.84M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $8.59M 10-Q · filed 2024-11-12 | $17.15M derived: sum of 2 quarters · filed 2024-11-12 | $25.88M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $8.56M 10-Q · filed 2024-11-12 | $17.29M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $8.73M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $27.45M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $7.07M 10-Q · filed 2023-11-02 | $13.89M derived: sum of 2 quarters · filed 2023-11-02 | $20.45M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $6.82M 10-Q · filed 2023-11-02 | $13.38M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $6.56M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $23.09M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $7.42M 10-Q · filed 2022-11-09 | $12.24M derived: sum of 2 quarters · filed 2022-11-09 | $17.52M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $4.82M 10-Q · filed 2022-11-09 | $10.11M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $5.29M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $12.55M 10-K · filed 2022-03-09 | ||||
| 2020-09-30 | $3.43M 10-Q · filed 2021-11-15 | $6.40M derived: sum of 2 quarters · filed 2021-11-15 | $8.97M derived: sum of 3 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $2.97M 10-Q · filed 2021-11-15 | $5.55M derived: sum of 2 quarters · filed 2021-11-15 | |||
| 2020-03-31 | $2.57M 10-Q · filed 2021-11-15 | ||||
| 2019-12-31 | $6.07M 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | $2.14M 10-Q · filed 2020-11-12 | $3.79M derived: sum of 2 quarters · filed 2020-11-12 | $4.00M derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $1.64M 10-Q · filed 2020-11-12 | $1.86M derived: sum of 2 quarters · filed 2020-11-12 | |||
| 2019-03-31 | $218.00K 10-Q · filed 2020-11-12 | ||||
| 2018-12-31 | $34.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |